These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 12070235

  • 1. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane.
    Yoon J, Giacopelli J, Granoff D, Kobayashi W.
    J Am Podiatr Med Assoc; 2002 Jun; 92(6):350-4. PubMed ID: 12070235
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 Jun; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 3. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 Jun; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 4. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS, Robson MC, Smiell JM, Perry BH.
    Wound Repair Regen; 1999 Jun; 7(3):141-7. PubMed ID: 10417749
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 6. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS.
    J Foot Ankle Surg; 1999 May; 38(3):227-31. PubMed ID: 10384364
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ.
    Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [Abstract] [Full Text] [Related]

  • 8. Treatment of scleroderma skin ulcers with a hydrocolloid membrane.
    Milburn PB, Singer JZ, Milburn MA.
    J Am Acad Dermatol; 1989 Aug; 21(2 Pt 1):200-4. PubMed ID: 2768569
    [Abstract] [Full Text] [Related]

  • 9. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK, Embil JM.
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [Abstract] [Full Text] [Related]

  • 10. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis.
    Mandracchia VJ, Sanders SM, Frerichs JA.
    Clin Podiatr Med Surg; 2001 Jan; 18(1):189-209, viii. PubMed ID: 11344978
    [Abstract] [Full Text] [Related]

  • 11. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
    Guzman-Gardearzabal E, Leyva-Bohorquez G, Salas-Colín S, Paz-Janeiro JL, Alvarado-Ruiz R, García-Salazar R.
    Adv Ther; 2000 Jan; 17(4):184-9. PubMed ID: 11185057
    [Abstract] [Full Text] [Related]

  • 12. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
    Smiell JM.
    Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
    [Abstract] [Full Text] [Related]

  • 13. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Aug; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 14. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
    Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF.
    Lancet; 1992 Jan 04; 339(8784):23-5. PubMed ID: 1345953
    [Abstract] [Full Text] [Related]

  • 15. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial.
    Senet P, Vicaut E, Beneton N, Debure C, Lok C, Chosidow O.
    Arch Dermatol; 2011 Aug 04; 147(8):926-30. PubMed ID: 21482863
    [Abstract] [Full Text] [Related]

  • 16. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
    Victor-Vega C, Desai A, Montesinos MC, Cronstein BN.
    Inflammation; 2002 Feb 04; 26(1):19-24. PubMed ID: 11936752
    [Abstract] [Full Text] [Related]

  • 17. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B.
    Internist (Berl); 2000 Jan 04; 41(1):A38. PubMed ID: 10712088
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov 04; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 19. Use of Regranex gel for diabetic foot ulcers.
    Piascik P.
    J Am Pharm Assoc (Wash); 1998 Nov 04; 38(5):628-30. PubMed ID: 9782698
    [No Abstract] [Full Text] [Related]

  • 20. Successful treatment of chronic wound in Klippel-Trenaunay syndrome with recombinant human platelet-derived growth factor-BB.
    Danikas D, Theodorou SJ, Wurmser E.
    Plast Reconstr Surg; 2002 Jun 04; 109(7):2608-9. PubMed ID: 12045617
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.